Loading...
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial
Pettitt, AR Jackson, R Cicconi, S Polydoros, F Yap, C Dodd, J Bickerstaff, M Stackpoole, M Khan, UT Carruthers, S
Pettitt, AR
Jackson, R
Cicconi, S
Polydoros, F
Yap, C
Dodd, J
Bickerstaff, M
Stackpoole, M
Khan, UT
Carruthers, S
Citations
Altmetric:
Abstract
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 3.46 MB
Keywords
Type
Meetings and Proceedings
Citation
Pettitt AR, Jackson R, Cicconi S, Polydoros F, Yap C, Dodd J, et al. Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. Haematologica. 2020.